The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 60-year-old former smoker with metastatic melanoma presented with the chief complaint of pulmonary infiltrates. Five years ago, he was diagnosed with a left chest wall melanoma. He underwent surgery but received no additional therapy for an American Joint Committee on Cancer stage T3a N0 M0 tumor that was 2.7 mm in depth with no ulceration of the epidermal surface. Resection margins were free of tumor. Four years later, he underwent excision of a raised pigmented skin lesion on his left calf that proved to be melanoma with positive margins. He underwent re-excision of melanoma but 2 months later developed a new left hip soft tissue nodule. Positron emission tomography (PET) -computed tomography showed multiple hypermetabolic lesions involving subcutaneous tissue, muscle osseous structures, and bone marrow, consistent with advanced melanoma. He began systemic therapy with ipilimumab and nivolumab. After four cycles of immunotherapy, he developed a nonproductive cough and mild dyspnea on exertion (Modified Medical Research Council dyspnea scale score of 2 [ie, he had to stop for breath when walking at his own pace on level ground]). A chest x-ray showed bilateral hilar enlargement, thickening of the right paratracheal stripe, and scattered patchy increased interstitial markings bilaterally. PET and chest computed tomography images showed enlarged mediastinal adenopathy with increased [18F]fluorodeoxyglucose uptake on PET and scattered diffuse 1- to 2-mm pulmonary nodules with ground-glass opacities ( Fig 1 ). The patient was referred for pulmonary input. The patient had smoked one pack of cigarettes per day for 35 years; he quit 6 years ago. He had no history of pneumonia, childhood asthma, or tuberculosis. His mother had asthma, but there was no other family history of asthma or other lung disease.
[1]
C. Rudin,et al.
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
,
2017,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2]
A. Giobbie-Hurder,et al.
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
,
2016,
JAMA oncology.
[3]
C. Powell,et al.
Update in Lung Cancer 2015.
,
2016,
American journal of respiratory and critical care medicine.
[4]
P. Jänne,et al.
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
,
2016,
Cancer Immunology Research.
[5]
F. Hodi,et al.
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
,
2015,
Cancer Immunology Research.
[6]
Shandra L. Protzko,et al.
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
,
2013,
American journal of respiratory and critical care medicine.
[7]
R. Booton,et al.
British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE
,
2013,
Thorax.
[8]
Jin-liang Kong,et al.
Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review.
,
2010,
Chest.
[9]
I. D. Johnston,et al.
American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias
,
2002
.
[10]
T. Pumarola,et al.
Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures
,
2001,
Thorax.
[11]
G. Raghu,et al.
American Thoracic Society Documents An Official American Thoracic Society Clinical Practice Guideline : The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease
,
2012
.